AMPH Q1 2025 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$171M-0.8% YoY

Gross Profit

$85M50.0% margin

Operating Income

$37M21.9% margin

Net Income

$25M14.8% margin

EPS (Diluted)

$0.51

QoQ Revenue Growth

-8.6%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$24M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$875M

Stockholders' Equity

$751M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$171M	$172M	-0.8%
Gross Profit	$85M	$87M	-2.3%
Operating Income	$37M	$48M	-22.3%
Net Income	$25M	$43M	-41.4%

Revenue Segments

Research and development services

$100,000100%

Geographic Segments

UNITED STATES

$163M95%

FRANCE

$8M5%

CHINA

$81,0000%